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Commensal non-toxigenic Bacteroides fragilis confers powerful health benefits to
the host, and has recently been identified as a promising probiotic candidate. We
previously isolated B. fragilis strain ZY-312 and identified it as a novel strain based
on 16S rRNA sequencing and morphological analyses. We also determined that ZY-
312 displayed desirable probiotic properties, including tolerance to simulated digestive
fluid, adherence, and in vitro safety. In this study, we aim to investigate whether ZY-
312 meets the safety criteria required for probiotic bacteria through comprehensive
and systematic evaluation. Consequently, the fatty acid profile, metabolite production,
and biochemical activity of strain ZY-312 were found to closely resemble descriptions
of B. fragilis in Bergey’s manual. Taxonomic identification of strain ZY-312 based on
whole genome sequencing indicated that ZY-312 and ATCC 25285 showed 99.99%
similarity. The 33 putative virulence-associated factors identified in ZY-312 mainly
encoded structural proteins and proteins with physiological activity, while the lack of bft
indicated that ZY-312 was non-toxigenic. In vivo safety was proven in both normal and
immune-deficient mice. The 11 identified antibiotic resistance genes were located on the
chromosome rather than on a plasmid, ruling out the risk of plasmid-mediated transfer
of antibiotic resistance. In vitro, ZY-312 showed resistance to cefepime, kanamycin,
and streptomycin. Finally, and notably, ZY-312 exhibited high genetic stability after 100
passages in vitro. This study supplements the foundation work on the safety evaluation
of ZY-312, and contributes to the development of the first probiotic representative from
the dominant Bacteroidetes phylum.
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INTRODUCTION
Commensal gut microbiota are important for host health. They contribute to maturation of
the immune system, building intestinal commensalism, resisting infectious microbes, digesting
indigestible carbohydrates, and producing certain nutrients such as vitamins and short-chain fatty
acids (Sekirov et al., 2010; Fijan, 2014). An increasing number of reports have confirmed the link
between intestinal flora disorder and disease, especially autoimmune and metabolic diseases (Fijan,
2014; Althani et al., 2016). Although it is not clear who takes the leap and how it happens, dominant
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members of the intestinal microbiota are now being examined
as potential probiotic candidates to assist in the treatment of
disease, or become alternatives to antibiotics (McKenney and
Pamer, 2015; Miquel et al., 2015).
Approved probiotic products based on intestinal microbiota
species mainly include lactic acid bacteria, Bifidobacterium, and
Escherichia coli (Foligne et al., 2013). However, there are currently
no probiotic representatives of the phylum Bacteroidetes, the
second-largest component of the intestinal flora. Recently,
non-toxigenic Bacteroides fragilis (NTBF) was shown to have
powerful health benefits to the host, and was recommended as
a probiotic candidate (Troy and Kasper, 2010; Hsiao et al., 2013;
Deng et al., 2016). It is therefore likely that B. fragilis will be the
first probiotic species from the phylum Bacteroidetes.
We previously isolated a novel B. fragilis strain ZY-312,
and have carried out basic safety assessments to test its
probiotic properties (Deng et al., 2016). Results of 16S rRNA
sequence analysis, tolerance to simulated digestive fluid, safety,
and adhesion to HT-29 cells suggested B. fragilis ZY-312
possessed desirable probiotic properties. However, these results
are not sufficient to definitively conclude that ZY-312 is
safe for use as a probiotic. According to the framework
of evaluations for probiotics from Europe (Miquel et al.,
2015) and by the Food and Agriculture Organization of
the United Nations and the World Health Organization
(FAO/WHO, 2002), thorough characterization of a strain,
including examination of the fatty acid profile, metabolite
production, and biochemical activity, evaluation of the potential
risk of transferable antibiotic resistance and genetic stability,
and verification of safety in animals, especially immunodeficient
animals, is an integral part of safety assessment (Miquel
et al., 2015). Taking advantage of whole genome sequencing
technology, we carried out a thorough characterization and
systematic evaluation of novel B. fragilis strain ZY-312 to
determine whether it meets the safety criteria required for
probiotics.
MATERIALS AND METHODS
Bacterial Strains and Culture Conditions
Strain ZY-312 was isolated from the feces of a healthy infant,
and was previously identified using 16S rRNA gene sequence
analysis (Deng et al., 2016). B. fragilis strain ATCC 25285 (also
known as NCTC 9343) was purchased from the American Type
Culture Collection (ATCC). The culture conditions and materials
were as described previously for strains ZY-312 and ATCC
25285 (Deng et al., 2016). For the microbial contamination
experiment, E. coli CBSLAM00087, Staphylococcus aureus
(S. aureus) CMCC(B) 26058, Salmonella enterica (S. enterica)
serotype Paratyphi B CBSLAM00994, Pseudomonas aeruginosa
(P. aeruginosa) CBSLAM00818, Candida albicans (C. albicans)
CMCC(F)98001, and Clostridium sporogenes (C. sporogenes)
CMCC(B) 64941 were obtained from the Academy of Military
Medical Science, Beijing, China. All strains were verified by
PCR amplification of 16S rRNA gene using the universal
primers 27 F (5′-AGAGTTTGATCCTGGCTCAG-3′) and 1492
R (5′-GGTTACCTTGTTACGACTT-3′) (Lanes D–J). Amplified
products were sequenced (Biomed).
Animals
For acute oral toxicity studies, 6- to 8-week-old female
specific pathogen-free (SPF) BALB/c mice and nude mice
were procured from the Animal Experiment Center of the
Academy of Military Medical Sciences, Beijing, China. The
animals had free access to tap water and standard rodent diet.
All of the animal experiments were performed in accordance
with the approval of the Animal Ethics Committee of the
Beijing Institute of Microbiology and Epidemiology, Beijing,
China.
Genome Sequencing, Assembly, and
Analysis
Total DNA was extracted from all strains using a DNA extraction
kit (Qiagen, USA) and the complete genome sequence of
strain ZY-312 was determined using an Illumina Hiseq 2000
sequencing system (Xu et al., 2015). A genome sequencing
library with an average insert size of 400 bp was generated,
and raw short-read sequences were filtered using Seqprep1 and
Sickle2 software. The genome was then assembled de novo
using SOAP de novo software (Luo et al., 2012). Accuracy of
the assembled genome sequence was evaluated by mapping all
raw reads onto the scaffolds using SOAPaligner (Cui et al.,
2013).
Gene prediction was carried out using Glimmer3.0 software
(Xu et al., 2015). Putative antibiotic resistance genes and
putative virulence factors were identified by BLAST analysis
of the antibiotic resistance genes database (ARDB)3 (Liu
and Pop, 2009) and the virulence factors database (VFDB)4
(Chen et al., 2005), respectively. A BLAST comparison was
performed between the genome sequences of strain ZY-312
and B. fragilis strain NCTC 9343 (GenBank accession number
NC_003228). A Perl script was written and the average nucleotide
identity (ANI) was calculated using BLAST. A neighbor-
joining phylogenetic tree was built using treebest based on
the ZY-312 complete genome sequence, the complete shotgun
sequences of other B. fragilis strains, and the complete genome
sequences of B. fragilis strains NCTC 9343 (GenBank accession
number NC_003228), YCH46 (GenBank accession number
NC_006347), and B. fragilis 638R (GenBank accession number
NC_016776).
General Characteristics of ZY-312
ZY-312 was cultured on Eosin methylene blue agar for 24 h
at 37◦C (E. coli as positive control), SS agar for 24 h at
37◦C (S. enterica serovar Paratyphi B as positive control),
Columbia agar containing blood and gentamicin for 48 h at 37◦C
(C. sporogenes as positive control), mannitol sodium chloride
agar for 24 h at 37◦C (S. aureus as positive control), NAC agar
1https://github.com/jstjohn/SeqPrep
2https://github.com/najoshi/sickle
3http://ardb.cbcb.umd.edu/
4http://www.mgc.ac.cn/VFs/main.htm
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TABLE 1 | Major fatty acids (A) and major metabolites (B) of Bacteroides
fragilis ZY-312.
Peak name Percentage (%)
(A)
C15:0 anteiso 32.21
C15:0 iso 17.29
C16:0 11.66
C16:0 3-OH 11.08
C14:0 1.82
C17:0 ante 3-OH 1.72
C18:0 1.68
C15:0 1.63
C18:1 CIS 9 1.37
Unable to distinguish 19.55
ZY-312 ATCC 25285
Time (s) Normalized
area
Time (s) Normalized
area
(B)
Acetic acid 1514 67.24 × 105 1513 27.65 × 105
Butanedioic acid 593 498.29 × 105 592 107.27 × 105
propionic acid 1353 2.65 × 105 1352 5.41 × 105
Phenylacetic acid 2404 1.33 × 105 2403 2.06 × 105
lactic acid 424 556.78 × 105 424 557.94 × 105
for 24 h at 37◦C (P. aeruginosa as positive control), Sabouraud
dextrose agar for 72 h at 28◦C (C. albicans as positive control),
rose bengal agar for 96 h at 28◦C (C. albicans as positive
control), and agar agar for 48 h at 37◦C (S. aureus as positive
control) for excluding microbial contamination. The major fatty
acids were analyzed using an HP6890 gas chromatograph (ver.
A 5.01), as previously described (Tan et al., 2010). Supernatant
from late-logarithmic phase ZY-312 and ATCC 25285 cultures
was collected by centrifugation for 10 min at 3000 × g,
and then analyzed by gas chromatography-mass spectrometry.
Carbon-source utilization analyses were carried out using a
Biolog AN microPlate test panel (Biolog, USA). Bacterial cells
were collected from logarithmic phase ZY-312 and ATCC 25285
cultures and resuspended at a concentration of 1.5 × 108 colony
forming units (cfu)/mL, and then inoculated into the test plate.
After incubating anaerobically for 16–24 h, test results were read
using a microplate reader (SpectraMax, M2), using deionized
water as a negative control. To test catalase activity, 3–5 drops
(about 100 µL) of 3% hydrogen peroxide (freshly prepared)
were dropped onto the center of precipitated bacterial cells on
microscope slides. To test gelatin liquefaction activity, bacteria
were inoculated into gelatin medium, tryptone soy broth (TSB,
OXIOD, UK) solidified with 15% gelatin, using a sterilized
needle. Plates were incubated at 37◦C for 48 h anaerobically,
then placed at 4◦C for 3–4 h. To determine hemolytic ability,
bacteria were anaerobically cultured on tryptone soy agar (TSA,
OXIOD, UK) supplemented with 5% (v/v) goat blood for 48 h
at 37◦C. To determine motility, bacteria were cultured on semi-
solid medium (TSB solidified with 0.5% agar) at 37◦C for 48 h
anaerobically.
Antibiotic Resistance Testing
Antibiotic resistance testing was performed using the minimum
inhibitory concentration (MIC) method as described previously
(Fernandez et al., 2005). Test antibiotics were chosen based
on the antibiotic resistance genes identified in the annotated
genome of ZY-312, with the following antibiotics included in
the analysis: cefoxitin, ceftriaxone, cefepime, trimethoprim,
clarithromycin, chloromycetin, levofloxacin, streptomycin,
kanamycin, tetracycline, vancomycin, and polymyxin B (NIFDC,
China). Although bcrA was identified in the genome, bacitracin
was not used because of high toxicity, while fosmidomycin
(rosA) is still undergoing testing and was therefore also excluded.
Quinupristin/dalfopristin, the targets of the vatB gene product
are not used in China, and there is no corresponding antibiotic
for ykkC. ZY-312 was cultivated anaerobically at 37◦C for
48 h at a concentration of 107 cfu/mL with antibiotics at
different concentrations. MIC was determined by measuring
optical density at 600 nm (OD600) with a microplate reader
(SpectraMax, M2).
Acute Toxicity to Normal Mice and Nude
Mice
To assess the acute toxicity of ZY-312, SPF BALB/c mice were
randomly assigned into five groups (n = 5–8). Each group was
administered with ZY-312 in a suspension containing 1 × 109,
5 × 1010, or 5 × 1011 cfu/day, 0.5 mL/day culture supernatant,
or 0.5 mL/day saline via oral gavage for 5 days. General
condition and body weight were observed daily for 17–18 days.
At the end of the experimental period, blood samples were
obtained for hematological and serum biochemistry analyses.
Stomach, colon, liver, and spleen were collected, weighed, and
prepared for histopathological examination. Nude mice were
orally administered with ZY-312 suspension at a dosage of
1 × 109 cfu/day for 3 days. General condition and bodyweight
were observed for 7 days.
Genetic Stability
To explore whether genetic variation occurs in ZY-312 during
in vitro passage, we continuously subcultured ZY-312 for 100
generations. Two parallel tubes were inoculated from an original
culture of ZY-312 in TSB supplemented with 5% fetal bovine
serum, and then incubated at 37◦C in an anaerobic glove box
(Bugbox, Ruskin) for 24 h. These initial cultures were designated
A0 and B0. Subsequent passages were performed by inoculating
1% of each culture into fresh medium every 24 h, until A100 and
B100 were obtained. Genetic variation was evaluated by complete
genome sequencing of strains A10, A25, A50, and A100, and B10,
B25, B50, and B100, and ANI was calculated for each generation.
Morphological variations were observed by colony examination,
Gram staining, and scanning electron microscopy (SEM) of A100
and B100, with wild-type ZY-312 used for comparison. Growth
of ZY-312, A100, and B100 under anaerobic conditions was also
examined over a 24-h period. Acute toxicity of A100 and B100
was detected in SPF mice at a dosage of 1 × 109 cfu/day for
3 days, with general condition and bodyweight observed for
7 days.
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TABLE 2 | Physiological and biochemical properties of B. fragilis ZY-312.
ZY-312 ATCC ZY-312 ATCC
(A)
Water − − Dulcitol − −
N-Acetyl-D-galactosamine + + D, L-α-Glycerol phosphate − −
N-Acetyl-D-glucosamine / + N-Acetyl-β-D-mannosamine − −
D-Fructose + + L-Fucose − −
Adonitol − − D-Galactose + +
Amygdalin + + D-Galacturonic acid − −
D-Arabitol − − Gentiobiose + +
Arbutin + + D-Gluconic acid − −
D-Cellobiose + + D-Glucosaminic acid − −
α-Cyclodextrin + + α-D-Glucose + +
β-Cyclodextrin + + Glucose-1-phosphate + +
Dextrin + + Glucose-6-phosphate + +
Glycerol − − α-Methyl-D-galactoside − −
i-Erythritol − − β-Methyl-D-galactoside + +
m-Inositol − − α-Methyl-D-glucoside − −
α-D-Lactose + + β-Methyl-D-glucoside − −
Lactulose + + Palatinose + +
Maltose + + D-Raffinose + +
Maltotriose + + L-Rhamnose − −
D-Mannitol − − Salicin + −
D-Mannose + + D-Sorbitol − −
D-Melezitose − − Stachyose + +
D-Melibiose + + Sucrose + +
3-Methyl-D-glucose + + D-Trehalose − −
Pyruvic acid methyl ester + + D-Lactic acid methyl ester − −
Acetic acid − − D-Malic acid − −
Formic acid − − L-Malic acid − −
Fumaric acid − − Propionic acid − −
Glyoxylic acid − − Pyruvic acid + +
α-Hydroxybutyric acid / / Turanose + +
β-Hydroxybutyric acid − − D-Saccharic acid − −
Itaconic acid − − Succinamic acid − −
α-Ketobutyric acid + + Succinic acid − −
α-Ketovaleric acid + + L-Asparagine − −
D,L-Lactic Acid − − m-Tartaric acid − −
L-Lactic acid − − Urocanic acid − −
L-Alaninamide − − L-Methionine − −
L-Alanine / + L-Phenylalanine − −
L-Alanyl-L-glutamine + / L-Serine − −
L-Alanyl-L-histidine / / L-Threonine − −
L-Alanyl-L-threonine + + L-Valine / +
Succinic acid monomethyl ester − − L-Valine plus L-aspartic acid − −
L-Glutamic acid − − 2′-Deoxy adenosine + +
L-Glutamine − − Inosine + +
Glycyl-L-aspartic acid + + Thymidine + +
Glycyl-L-glutamine − − Uridine + +
Glycyl-L-methionine − − Glycyl-L-proline − −
Thymidine-5′-monophosphate − − Uridine-5′-monophosphate − /
ZY-312 ATCC 25285
(B)
Catalase assay Positive Positive
Gelatin liquefaction test Weakly positive Weakly positive
Hemolysis test Negative Negative
Dynamic test Negative Negative
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TABLE 3 | Putative virulence-associated genes identified in the genome of B. fragilis ZY-312.
Gene ID VFDB_ID Name Function
YDGL001582 VF0091 Alginate algI Alginate O-acetyltransferase AlgI
YDGL004163 VF0003 Capsule cap8E Capsular polysaccharide synthesis enzyme Cap8E
YDGL004164 VF0003 Capsule cap8G Capsular polysaccharide synthesis enzyme Cap8G
YDGL002547 VF0003 Capsule cap8M Capsular polysaccharide synthesis enzyme Cap8M
YDGL002015 VF0003 Capsule cap8O Capsular polysaccharide synthesis enzyme Cap8O
YDGL002539 VF0003 Capsule cap8O Capsular polysaccharide synthesis enzyme Cap8O
YDGL002014 VF0144 Capsule cps4I UDP-N-acetylglucosamine-2-epimerase
YDGL002540 VF0144 Capsule cps4I UDP-N-acetylglucosamine-2-epimerase
YDGL001235 VF0274 Capsule cpsJ Glycosyl transferase CpsJ(V)
YDGL004140 VF0323 Capsule fcl Putative fucose syntheses
YDGL002177 VF0323 Capsule glf UDP-galactopyranose mutase
YDGL001165 VF0072 ClpC clpC Endopeptidase Clp
YDGL002866 VF0072 ClpC clpC Endopeptidase Clp
YDGL002842 VF0074 ClpP clpP ATP-dependent Clp protease
YDGL001133 VF0215 Dispersin aatC AatC ATB binding protein of ABC transporter
YDGL003303 VF0215 Dispersin aatC AatC ATB binding protein of ABC transporter
YDGL003305 VF0215 Dispersin aatC AatC ATB binding protein of ABC transporter
YDGL003564 VF0215 Dispersin aatC AatC ATB binding protein of ABC transporter
YDGL003567 VF0215 Dispersin aatC AatC ATB binding protein of ABC transporter
YDGL004218 VF0215 Dispersin aatC AatC ATB binding protein of ABC transporter
YDGL002299 VF0273 Flagella fleQ Transcriptional regulator FleQ
YDGL002756 VF0334 HSI-I PA0073 ATP-binding component of ABC transporter
YDGL002122 VF0159 Hsp60 htpB Hsp60, 60K heat shock protein HtpB
YDGL004141 VF0367 LPS gmd GDP-mannose 4,6-dehydratase
YDGL001251 VF0106 MgtBC mgtB Mg2+transport protein
YDGL002018 VF0153 Mip mip Macrophage infectivity potentiator (Mip)
YDGL003334 VF0298 MprAB mprA MprB, sensor kinas. MprA, transcriptional factor
YDGL003892 VF0392 O-Antigen ddhA Glucose-1-phosphate cytidylyltransferase
YDGL003891 VF0392 O-Antigen ddhB CDP-glucose 4,6-dehydratase
YDGL003902 VF0392 O-Antigen galE UDP-glucose 4-epimerase
YDGL003150 VF0319 PanC/PanD panD panD
YDGL003842 VF0169 SodB sodB Superoxide dismutase
YDGL003057 VF0101 Vi antigen tviB Vi polysaccharide biosynthesis protein,
UDP-glucose/GDP-mannose dehydrogenase
Experimental Replicates and Statistical
Methods
All experiments were performed at least in triplicate using
independent assays, and values were expressed as the
mean ± standard error. An unpaired Student’s t-test was
performed to determine statistically significant differences in
the acute toxicity assays. A p-value of <0.05 was considered
statistically significant.
RESULTS
Morphological Characteristics
Strain ZY-312 only grew under anaerobic conditions
(Supplementary Figure S1), with no growth observed
under aerobic conditions or in 5% CO2, implying it was an
obligate anaerobe. Microbial contamination was excluded by
culturing ZY-312 in different culture media under different
conditions (Supplementary Figure S2). ZY-312 formed
circular, low convex, semi-opaque colonies following anaerobic
cultivation on blood agar plates (Supplementary Figure S1).
Cells were Gram-negative, and shown to be rod shaped
with rounded ends by scanning electrochemical microscopy
(Supplementary Figure S1). This morphology matched the
descriptions of B. fragilis in Bergey’s manual (Krieg et al., 2001).
General Characteristics
The major fatty acids of ZY-312 were C15:0 anteiso, C15:0 iso,
C16:0, and C16:0 3-OH (Supplementary Figure S3 and Table 1A).
The major products in the culture supernatant of ZY-312
were lactic acid, acetic acid, succinic acid, propionic acid, and
phenylacetic acid (Table 1B). ZY-312 and ATCC 25285 differed in
their ability to metabolize L-valine, salicin, L-alanine, L-alanyl-L-
glutamine, and N-acetyl-D-glucosamine (Table 2A). Both strains
were positive for catalase activity, weakly positive for gelatin
liquefaction, and negative for hemolytic activity and motility
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TABLE 4 | Putative antibiotic resistance genes (A) identified in the genome
of Bacteroides fragilis ZY-312, and minimum inhibitory concentration
values (B) for each of the corresponding antibiotics.
Gene ID Name Drug
(A)
YDGL002306 BcrA Bacitracin
YDGL000449 BL2e_cepa Cephalosporin
YDGL000258 dfrA22 Trimethoprim
YDGL003477 MefA Macrolide
YDGL001150 MexF Chloramphenicol, Fluoroquinolone
YDGL000604 MexY Aminoglycoside, Glycylcycline
YDGL003440 RosA Fosmidomycin
YDGL003171 tet37 Tetracycline
YDGL003704 VanRA Vancomycin, Teicoplanin
YDGL003646 VatB Streptogramin_A
YDGL000090 YkkC na_antimicrobials
Antibiotic ZY-312 ATCC 25285
(B)
Cefoxitin MIC = 2.0 MIC = 1.5
Ceftriaxone MIC < 64 MIC < 64
Cefepime MIC > 32 MIC > 32
Trimethoprim MIC < 16 MIC < 16
Clarithromycin MIC < 8 MIC < 8
Chloromycetin MIC < 32 MIC < 32
Levofloxacin MIC < 8 MIC < 8
Streptomycin MIC > 1200 MIC > 1200
Kanamycin MIC > 50 MIC > 50
Tetracycline MIC < 16 MIC < 16
Vancomycin 4 < MIC < 8 4 < MIC < 8
Polymyxin B MIC > 8 MIC > 8
Bacitracin was eliminated because of high toxicity. Fosmidomycin is still being
researched and was therefore excluded. Quinupristin/dalfopristin are not available
in China and were also excluded. No corresponding antibiotic exists for the ykkC
gene product.
(Table 2B). The physiological and biochemical characteristics of
ZY-312 were in accordance with B. fragilis as described in Bergey’s
manual (Krieg et al., 2001).
Genetic Characteristics
The phylogenetic trees generated from the whole genome
sequence of ZY-312 and other B. fragilis strains are shown in
Supplementary Figures S5, S6. ZY-312 and ATCC 25285 had an
ANI of 99.99%. In total, 33 putative virulence factors (Table 3)
and 11 antibiotic resistance genes (Table 4A) were annotated in
the ZY-312 genome based on a minimum of 40% amino acid
homology. The complete genome was 4,558,494 bp in length and
contained on a single chromosome, with an average GC content
of 43.08%, consistent with that of B. fragilis (41–44%) (Krieg et al.,
2001). All drug-resistance genes were located on the chromosome
rather than on plasmids.
Putative Virulence Factors
Through BLAST analysis of the VFDB, a total of 33 virulence
factor homologs were identified in the genome of ZY-312
(Table 3). Most of these putative virulence genes encoded
proteins involved in cellular structure or physiological activities,
and none had previously been reported as being related to the
pathogenesis of B. fragilis. Notably, bft was not present in the
genome of ZY-312, indicating that it is a non-toxigenic strain.
Antibiotic Resistance
Antibiotic resistance tests were performed based on the
antibiotic resistance genes identified in the genome of YZ-312
(Table 4A), and results are summarized in Table 4B. Based
on guidelines for antibiotic resistance breakpoints (Russell and
Sambrook, 2002; National Center for Clinical Laboratories,
2006), ZY-312 showed resistance to cefepime, kanamycin, and
streptomycin, but was susceptible to ceftriaxone, trimethoprim,
clarithromycin, chloramphenicol, tetracycline, and levofloxacin.
Without available guidelines for B. fragilis, resistance of ZY-312 to
vancomycin and polymyxin B could not be confirmed; however,
we observed that 4–8 µg/mL vancomycin and >8 µg/mL
polymyxin B were sufficient to inhibit ZY-312 growth in vitro.
ZY-312 Is Non-pathogenic in Both
Normal and Immune-Deficient Mice
To confirm the in vivo safety of ZY-312, acute toxicity
experiments were performed in both normal SPF BALB/c
mice and nude mice. Lacking a thymus and an immune
response, nude mice are an ideal animal model for evaluating
probiotic safety. No death was observed in the BALB/c mice
during the toxicity experiments, no treatment-related toxicity
was observed, and no significant difference in body weight
was noted between low, medium (Supplementary Figure S4),
and high (Figure 1A-1) dose treatment groups and the
control group, respectively. Similarly, no difference was found
between the culture supernatant-treated group and the control
group (Figure 1A-2). In addition, there was no obvious
histopathological damage in the stomach, colon, liver, or spleen
of BALB/c mice from the high dosage group (Figure 1B). There
were also no significant differences in blood routine index or
hepatorenal function between the high dose and control groups
(data not shown). For the immune-deficient mouse toxicity
experiments, ZY-312 again had no deleterious effects on body
weight (Figure 1A-3).
ZY-312 Is Genetically and Phenotypically
Stable
To explore whether ZY-312 undergoes major genomic
rearrangements during passage, the stability of ZY-312
was examined after 100 generations in vitro. A100 and B100
were morphologically identical to the original ZY-312 strain
(Figure 2A) based on visual inspection, optical microscopy,
and SEM. The growth characteristics of A100 and B100
(Figure 2B) were not significantly different from those of
ZY-312. Furthermore, following oral administration of A100 or
B100 at a dose of 1 × 109 cfu/day for 3 days, mice did not show
any clinical symptoms or weight loss during the observation
period (Figure 2C). The calculated ANI values from each
generation were at least 99.98% (Figure 2D).
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FIGURE 1 | ZY-312 is non-pathogenic in mice. (A) Changes in body weight (%) per day were observed for the experimental and control groups. (A-1) Specific
pathogen-free (SPF) BALB/c normal mice (n = 8) were treated with 5 × 1011 colony forming units (cfu)/day ZY-312 for 5 days and observed for 18 days. A control
group was treated with saline. (A-2) SPF normal mice (n = 16) were treated with culture supernatant (0.5 mL/day) for 5 days and observed for 17 days. Tryptic soy
broth was used for the control group. (A-3) Nude mice (n = 5) were treated with ZY-312 at a concentration of 1 × 109 cfu/day for 3 days and observed for 7 days.
The control group were treated with saline. (B) Light micrograph images of the stomach, colon, liver, and spleen from mice belonging to the high dosage group
(upper) and control group (lower). No significant lesions were observed (mean ± SE; NS, not significant, t-test).
DISCUSSION
According the recent reports, non-toxic B. fragilis now is
regarded as a commensal constituent with potential as a
probiotic candidate (Hsiao et al., 2013), because of powerful
immunoregulatory benefits and health-promoting effects it
owns. Although B. fragilis makes up a very small part of
the human intestinal flora, it plays a unique role in the
maturation of the host immune system (Mazmanian et al.,
2005; Troy and Kasper, 2010). Mono-colonization of mice
with B. fragilis was sufficient to correct systemic immune
defects in germ-free mice by stimulating maturation of splenic
CD4+ T cells (Mazmanian et al., 2005) and rebalancing the
Th1/Th2 response. Furthermore, B. fragilis can direct an anti-
inflammatory response, conferring protection in experimental
mouse models of colitis (Mazmanian et al., 2008; Round
and Mazmanian, 2010) and of autoimmune encephalomyelitis
(Ochoa-Reparaz et al., 2010). Those observed effects were
absent in mice treated with a B. fragilis PSA-deficient mutant
strain. PSA is a dominant member of capsular polysaccharide
complex (CPC) at the surface of B. fragilis, and contains a
zwitterionic motif. B. fragilis is associated with clinical anaerobic
infection and the CPC, especially PSA plays a key role in arising
those diseases (Lindberg et al., 1982; Mazmanian and Kasper,
2006). Nevertheless, the role of PSA plays in intra-abdominal
abscess probably is beneficial rather than harmful, since the
inflammation aroused by PSA helps limit the spread of other
gut bacteria and prevent more serious infection (Mazmanian and
Kasper, 2006; Deng et al., 2016). Instead of being recognized
as virulence factor, recently, PSA has been reconsidered as a
symbiosis factor with health-promoting effect (Mazmanian et al.,
2008).
Therefore, under overall considerations about the pros and
cons, we believe non-toxic B. fragilis is a good choice for probiotic
candidate and we decided to isolate a new strain of B. fragilis
named ZY-312 (Deng et al., 2016) and explore its safety whether
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FIGURE 2 | ZY-312 is genetically stable. (A) Gram-stained ZY-312, A100, and B100 cells following anaerobic culture on tryptic soy agar (5% sheep blood) for 48 h
at 37◦C. Observation were made using a light microscope (4000×) and a scanning electron microscope (30000×). (B) Growth curves of ZY-312, A100, and B100
cultured anaerobically for 24 h. (C) SPF BALB/c normal mice (n = 8) were treated with A100 or B100 at a concentration of 1 × 109 cfu/day for 3 days and observed
for 7 days. A control group was treated with saline. (D) Average nucleotide identities were calculated between each generation.
satisfy the criteria required for probiotic bacteria. Although the
health benefits of B. fragilis are generally recognized, much work
still needs to be done to obtain certification of this species
as a probiotic. Probiotics are defined as non-pathogenic live
microorganisms that confer health benefits to the host when
administered in adequate amounts (FAO/WHO, 2002). As living
microorganisms with the potential for infection or in situ toxin
production, probiotics should fulfill health and safety claims
before entering the market. Safety assessment is the chief task
for certifying a probiotic, as any adverse effects should be
predicted in advance. Accordingly (FAO/WHO, 2002; Miquel
et al., 2015), correct identification, sufficient characterization, and
evaluation of potential risk and probiotic properties are integral
for evaluation of a new probiotic.
Previously, we demonstrated that novel strain ZY-312, isolated
from the feces of a healthy breast-fed infant, possessed similar
morphological and growth characteristics to typical B. fragilis
strains, as well as exhibiting desirable probiotic properties,
including tolerance to air, simulated gastric fluid (pH 3.0),
simulated intestinal fluid and ox bile (pH 6.8), adhesion, and
in vitro safety in colon cells (Deng et al., 2016). Based on
these results, we carried out a more thorough characterization
and systemic evaluation of ZY-312 in the current study. As
recommended (FAO/WHO, 2002), phenotypic testing, fatty acid
analysis, metabolite production, biochemical activity, and in vivo
toxicity testing, in combination with genetic analysis, taxonomic
identification, and putative virulence and antibiotic resistance
gene identification analysis, were performed to determine
whether ZY-312 is safe for use as a probiotic. The major fatty acids
and metabolic products of ZY-312 closely resemble descriptions
of B. fragilis in Bergey’s manual, as do the results of biochemical
activity testing. Our previous work showed that the 16S rRNA
sequence of ZY-312 was 99% identical to that of B. fragilis
strain ATCC 28285. However, 16S rRNA sequence analysis
has potential drawbacks for separating closely related species
because of low taxonomic resolution. Whole genome sequencing
identifies taxa with higher taxonomic resolution, and provides
more information about gene function, such as putative virulence
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factors and antibiotic resistance genes (Rijkers et al., 2011; Miquel
et al., 2015). Taking advantage of whole genome sequencing
technology in the current study, we showed that ZY-312 and
ATCC 25285 shared 99.99% ANI, and were derived from
the same origin (Supplementary Figure S5), consistent with
previous results. Furthermore, a total of 33 putative virulence
factors and 11 antibiotic resistance genes were annotated in
the genome of ZY-312 through comparative analysis with the
VFDB and the ARDB, respectively. The putative virulence factors
consisted of structural proteins and proteins with physiological
activity, and none had previously been reported in association
with the pathogenesis of B. fragilis. Because of the absence of bft,
ZY-312 was identified as a NTBF strain.
There are many reports claiming probiotic safety based on an
assessed lack of infectivity in normal animals (Bernardeau et al.,
2002; Shokryazdan et al., 2016). However, confidence would be
increased if assessment could be performed in immunodeficient
animals (FAO/WHO, 2002). Therefore, we examined the safety
of ZY-312 in both normal and immunodeficient mice. The
SPF normal mice treated with high doses or supernatant
of ZY-312 did not display any significant strain-related
toxigenic symptoms, based on the assessment of body weight
changes, histopathological examination, blood routine index, and
hepatorenal function. Notably, ZY-312 also proved safe in nude
mice (Figure 1A-3).
The FAO/WHO recommends that probiotic strains should
be fully characterized, including determination of antibiotic
resistance patterns, and should have no risk of transferring
antibiotic resistance (FAO/WHO, 2002). Theoretically,
consumption of probiotics with transferrable antibiotic resistance
genes might lead to refractory infections if multiple antibiotic
resistance genes are transferred to a pathogen (Borchers et al.,
2009; Sanders et al., 2010). We demonstrated that there is
no risk of ZY-312 spreading antibiotic resistance because all
identified drug-resistance genes (Table 4A) were located in the
chromosome rather than on a plasmid. Moreover, we verified
the antibiotic resistance phenotype of ZY-312, and discovered
that it is resistant to cefepime, kanamycin, and streptomycin,
but susceptible to ceftriaxone, trimethoprim, clarithromycin,
chloramphenicol, tetracycline, and levofloxacin. The MICs of
vancomycin and polymyxin B for ZY-312 were also identified
(Table 4B). The inconsistencies between genotype and observed
phenotype might stem from the fact that putative antibiotic
resistance genes were annotated based on 40% amino acid
homology, meaning that some genes were incorrectly identified
in the genome of ZY-312, and are likely not present.
As potential genetic variation might lead to unpredictable
risk, genetic stability should also be confirmed prior to starting
large-scale production of ZY-312-based probiotics (Sanders
et al., 2010). We confirmed that following in vitro passage
of 100 generations from the original strain of ZY-312, there
was no significant difference between A100, B100, and the
parental strain with respect to morphological characteristics and
growth features. No in vivo toxicity was observed for A100
or B100, and the ANI between each generation was at least
99.98%, demonstrating that ZY-312 has a high degree of genetic
stability.
CONCLUSION
We confirmed that ZY-312 is a NTBF strain, without potential
virulence factors or risk of spreading antibiotic resistance genes.
As well as having desirable probiotic properties (Deng et al.,
2016), ZY-312 has a high degree of genetic stability and is non-
pathogenic, even to immune-deficient mice. Therefore, ZY-312
is most likely safe for use in future probiotic applications. This
study supplements the initial safety assessment work already
carried out for ZY-312, and contributes to the development of the
first probiotic representative from the dominant Bacteroidetes
phylum.
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FIGURE S1 | (A) Colonies of ZY-312 on tryptone soy agar (5% sheep blood)
following culture in 5% CO2 (A-A), air (A-B), or anaerobically (A-C) for 48 h at
37◦C. (B) Cells observed under light microscope following Gram staining (4000×).
(C) Cells observed under scanning electron microscope (5000×).
FIGURE S2 | Confirmation of no microbial contamination. (A) Escherichia
coli and ZY-312 cultured on Eosin methylene blue agar for 24 h at 37◦C. (B)
Salmonella enterica serovar Paratyphi B and ZY-312 cultured on SS agar for 24 h
at 37◦C. (C) Clostridium sporogenes and ZY-312 cultured anaerobically on
Columbia agar containing blood and gentamicin for 48 h at 37◦C. (D)
Staphylococcus aureus and ZY-312 cultured on mannitol sodium chloride agar for
24 h at 37◦C. (E) Pseudomonas aeruginosa and ZY-312 cultured on NAC agar for
24 h at 37◦C. (F) Candida albicans and ZY-312 cultured on Sabouraud dextrose
agar for 72 h at 28◦C. (G) S. aureus and ZY-312 cultured on agar agar for 48 h at
37◦C. (H) C. albicans and ZY-312 cultured on rose bengal agar for 96 h at 28◦C.
FIGURE S3 | The major fatty acids of ZY-312 as identified by gas
chromatography.
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FIGURE S4 | Acute toxicity of ZY-312 to mice. Changes in body weight (%)
per day were observed for the experimental and control groups. (A)
Specific pathogen-free (SPF) BALB/c normal mice (n = 5) were treated with
ZY-312 at a concentration of 1 × 109 cfu/day for 5 days and observed for
15 days. The control group mice were treated with saline. (B) SPF normal mice
(n = 5) were treated with ZY-312 at a concentration of 5 × 1010 cfu/day for 5 days
and observed for 18 days. Tryptic soy broth was used to treat the control group.
No significant weight loss was observed in any of the animals (mean ± SE; NS,
not significant, t-test).
FIGURE S5 | Phylogenetic tree based on complete shotgun sequences
showing the relationship between Bacteroides fragilis ZY-312 and closely
related species. The tree was constructed using the neighbor-joining
method.
FIGURE S6 | Phylogenetic tree based on complete genome sequences
showing the relationship between B. fragilis strain ZY-312, B. fragilis
NCTC 9343, B. fragilis YCH46, and B. fragilis 638R. The tree was constructed
using the neighbor-joining method.
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